Stockreport

Nkarta: Down 50% Since March With A Clinical Catalyst Ahead [Seeking Alpha]

Nkarta, Inc.  (NKTX) 
PDF The company's pipeline includes NKX019, a CAR-NK cell therapy with potential in cancer and autoimmune disease. NKTX has already produced some data with NKX019 in onco [Read more]